The following information was received from the
Georgia Department of Natural Resources (GADNR),
Georgia Radioactive Materials Program, via email:
On Monday April 1, 2024, GADNR received notification from our licensee, [license number] GA 796-1, of a brachytherapy seed migration post implant of Iodine-125 seeds. The reporting official is the hospitals Manager of Radiation Physics [MRP]. [The MRP] was contacted via cell phone today, April 2, 2024, for further information. [They] stated that each seed was approximately 0.635 mCi, totaling 18.62 mCi. The patient was seen some time last week and their computed tomography (CT) results were analyzed yesterday during their post implant CT exam. The prescription was 145 Gy to the prostate using 18.62 mCi of I-125. The D90 to the target was 46.2 percent instead of the expected 80-120 percent on the post implant dosimetry. [The MRP] will be sending a full report of this incident within the next 15 days. [GANDR] will follow up with more information at a later date.
- * * RETRACTION ON 4/9/24 AT 0807 EDT FROM ANASTASIA BENNETT TO BILL GOTT * * *
The following information was received from the Georgia Department of Natural Resources (GANDR), Georgia Radioactive Materials Program, via email:
GADNR is requesting closure of the incident case as it does not meet the reporting criteria outlined in 10 CFR 35.3045(a)(2)(i)(2) for permanent implant brachytherapy. Specifically, the incident does not involve the administration of byproduct material or radiation from byproduct material resulting in a total source strength administered differing by 20 percent or more from that documented in the post-implantation portion of the written directive, excluding instances where sources migrate outside the treatment site.
Notified R1DO (DeFrancisco) and NMSS Events Notification via email.
Georgia Incident number: 83
A Medical Event may indicate potential problems in a medical facility
s use of radioactive materials. It does not necessarily result in harm to the patient.